Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection

Ohya, K.; Kawaoka, Tomokazu; Imamura, Michio; Morio, Kei; Nakahara, Takashi; Murakami, Eisuke; Yamauchi, Masami; Hiramatsu, Akira; Tsuge, Masataka; Chayama, Kazuaki

doi:10.2169/internalmedicine.3824-19

Cited by 3 publications

(4 citation statements)

References 22 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No SAE or early discontinuation of therapy were observed. After DAA therapy, the emotional functioning of patients and their mothers improved [16,17].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study

Pawlowska,

Dobrowolska,

Moppert

et al. 2023

JCM

View full text Add to dashboard Cite

The aim of the study was to analyze the effectiveness and safety of anti-HCV treatment based on a pangenotypic direct-acting antiviral (DAA) regimen with glecaprevir/pibrentasvir (GLE/PIB) in children. The multi-center study was conducted in HCV-infected children who were treated in the period from November 2022 to January 2023. The analysis included 23 pediatric patients with a mean (SD) age of 9.61 (3.68) years. The cohort included 13 girls and 10 boys. The most common HCV genotypes were GT1b (n = 9, 39.1%), GT1a (n = 6, 26.1%) and GT3 (n = 5, 21.7%). The SVR was assessed at 12 weeks after the end of treatment and was 100% for both girls and boys. The conducted study showed a very good tolerance of the treatment in the entire analyzed group and confirmed a very high efficacy and safety for 8-week treatment with GLE/PIB in children over three years of age. It seems that our study is the first on the real-world use of an 8-week GLE/PIB pangenotypic therapy in a group of children aged 3–12 years and the first in Europe for adolescents aged 12–17.

show abstract

“…No SAE or early discontinuation of therapy were observed. After DAA therapy, the emotional functioning of patients and their mothers improved [16,17].…”

Section: Discussionmentioning

confidence: 99%

“…Twenty-five patients infected with HCV genotypes 1b, 2a, 2b and 2b/1b, including 15 girls and 10 boys, were enrolled in the multicenter study. The median age was 13 years (range [12][13][14][15][16][17]. A total of 12/25 (96%) adolescents achieved SVR.…”

Section: Discussionmentioning

confidence: 99%

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study

Pawlowska,

Dobrowolska,

Moppert

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…However, in 1 study, a girl aged 10 years and 8 months achieved SVR12 with no AEs after 8 weeks of glecaprevir/ pibrentasvir treatment. 49 This study was limited by high heterogeneity between clinical trials. Although the SVR12 rates in the ITT populations in the individual trials were all >90%, there was evidence of high heterogeneity between trials (SVR 12 rates: ITT population, I 2 =75%; mITT population, I 2 =72%).…”

Section: Discussionmentioning

confidence: 99%

“…However, in 1 study, a girl aged 10 years and 8 months achieved SVR12 with no AEs after 8 weeks of glecaprevir/pibrentasvir treatment. 49 …”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patients: A Systematic Review and Meta-analysis

Wang

Xiao

et al. 2020

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Background and Aims: Glecaprevir/pibrentasvir is a pangenotypic regimen recently approved for the treatment of chronic hepatitis C virus (HCV) infection. The objective of the present review was to summarize the findings from clinical trials to understand how patient-related factors influence glecaprevir/pibrentasvir efficacy (sustained virologic response rates at 12 weeks' after treatment [referred to as SVR12]) and safety. Methods: Data from 21 phase III clinical trials were analyzed. Results: The integrated efficacy analysis included 4,817 patients. Findings showed 97.5% of all included patients with chronic HCV achieved SVR12 in the intention-to-treat population. SVR12 rate was >95% across subgroups of interest. The integrated safety analysis included 4,015 patients. Findings showed that 64.1% of patients reported an adverse event, and <0.1% of patients reported a serious adverse event related to glecaprevir/pibrentasvir. Conclusions: These results indicate that the 8-or 12-week glecaprevir/pibrentasvir treatment is effective for patients infected with HCV genotypes 1-6 without or with compensated cirrhosis, with good safety profiles, irrespective of treatmentexperience. Glecaprevir/pibrentasvir is a good option for patients with human immunodeficiency virus/HCV coinfection and comorbid HCV and severe renal impairment.

show abstract

Cascade of care for children and adolescents with chronic hepatitis C

Rogers¹,

Balistreri²

2021

WJG

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection presents a significant global public health burden. In 2015, over 400000 deaths worldwide were attributed to HCV infection. This led the World Health Organization (WHO) in 2016 to set the ambitious goal of eliminating HCV by 2030. Adult-centered guidelines have been established in order to provide direction for healthcare professionals, allowing integration of the newest screening policies and therapeutic strategies into their practices. However, for children and adolescents, HCV is a significant, unrecognized public health problem. HCV infection rates in the United States in women of childbearing age and those who are pregnant have increased in parallel with the rising opioid epidemic. An estimated 29000 women with HCV infection gave birth each year from 2011 to 2014 in the United States, with approximately 1700 of their infants being infected with HCV. Newer HCV-specific therapeutics, namely direct acting antivirals (DAA), has brought a new and highly successful approach to treatment of hepatitis C. Recent studies have confirmed similar levels of effectiveness and safety of DAA therapies in the pediatric population. Thus, an enhanced cascade of care, which should include the population under 18 years of age, can help achieve the WHO goal by focusing on elimination in the youngest populations. This review will present an overview of the natural history, clinical features, and management of HCV in children and adolescents.

show abstract

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection

Cited by 3 publications

References 22 publications

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study

Efficacy and Safety of Glecaprevir/Pibrentasvir for Chronic Hepatitis C Patients: A Systematic Review and Meta-analysis

Cascade of care for children and adolescents with chronic hepatitis C

Contact Info

Product

Resources

About